LCI Lannett Co Inc
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. Its products include aqueous vitamin D 4; escitalopram oxalate; ranitidine syrup; danazol; primidone; and isonlazid. The company was founded in 1942 and is headquartered in Philadelphia, PA.
Company profile
Ticker
LCI
Exchange
CEO
Timothy C. Crew
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
IRS number
230787699
LCI stock data
()
Calendar
7 May 19
24 Aug 19
30 Jun 20
News
Company financial data Financial data
| Quarter (USD) | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|
| Revenue | 172.79M | 193.72M | 155.05M | 170.91M | |
| Net income | 10.65M | 12.36M | -287.53M | -11.36M | |
| Diluted EPS | 0.27 | 0.32 | -7.65 | -0.3 | |
| Net profit margin | 6.16% | 6.38% | -185% | -6.65% | |
| Operating income | 33.38M | 36.68M | -341.78M | 8.6M | |
| Net change in cash | 41.43M | 13.45M | 51.74M | -15.43M | |
| Cash on hand | 205.21M | 163.77M | 150.33M | 98.59M | |
| Cost of revenue |
| Annual (USD) | Jun 18 | Jun 17 | Jun 16 | Jun 15 | |
|---|---|---|---|---|---|
| Revenue | 684.56M | 633.34M | 542.49M | 406.84M | |
| Net income | 28.69M | -581K | 44.78M | 149.92M | |
| Diluted EPS | 0.75 | -0.02 | 1.2 | 4.04 | |
| Net profit margin | 4.19% | -0.09% | 8.25% | 36.85% | |
| Operating income | 129.7M | 86.45M | 130.76M | 226.49M | |
| Net change in cash | -19.15M | -107.03M | 24.43M | 94.75M | |
| Cash on hand | 98.59M | 117.74M | 224.77M | 200.34M | |
| Cost of revenue | 100.48M |
Financial data from Lannett earnings reports
Financial report summary
?Competition
Impax Laboratories
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
advisory, Alabama, assist, Carolina, committed, committee, Commonwealth, extinguishment, Georgia, Inquiry, Island, located, Michigan, Montana, Nevada, ongoing, Rhode, unfavorable, Virginia, West, written
Removed:
removed
Financial reports
10-Q
2019 Q3
Quarterly report
7 May 19
10-Q
2019 Q2
Quarterly report
7 Feb 19
10-Q
2019 Q1
Quarterly report
8 Nov 18
10-K
2018 FY
Annual report
28 Aug 18
10-Q
2018 Q3
Quarterly report
8 May 18
10-Q
2018 Q2
Quarterly report
8 Feb 18
10-Q
2018 Q1
Quarterly report
8 Nov 17
10-K
2017 FY
Annual report
28 Aug 17
10-Q
2017 Q3
Quarterly report
5 May 17
10-Q
2017 Q2
Quarterly report
3 Feb 17
Current reports
8-K
Departure of Directors or Certain Officers
1 Aug 19
8-K
Entry into a Material Definitive Agreement
8 Jul 19
8-K
Cost Associated with Exit or Disposal Activities
17 Jun 19
8-K
Lannett Announces Cfo Retirement
24 May 19
8-K
Departure of Directors or Certain Officers
23 May 19
8-K
Other Events
21 May 19
8-K
Results of Operations and Financial Condition
7 May 19
8-K
Other Events
21 Mar 19
8-K
Lannett Announces Record Net Sales In the Fiscal 2019 Second-quarter Financial Results; Raises Guidance for Fiscal 2019
7 Feb 19
8-K
Submission of Matters to a Vote of Security Holders
25 Jan 19
Registration and prospectus
S-8
Registration of securities for employees
22 Mar 19
S-3ASR
Automatic shelf registration
13 Feb 18
S-3ASR
Automatic shelf registration
12 May 17
S-8
Registration of securities for employees
23 Jan 14
25
Voluntary exchange delisting
12 Dec 13
8-A12B
Registration of securities on exchange
2 Dec 13
424B5
Prospectus supplement for primary offering
4 Oct 13
FWP
Free writing prospectus
4 Oct 13
424B5
Prospectus supplement for primary offering
3 Oct 13
S-3/A
Shelf registration (amended)
19 Nov 12
Proxies
DEFA14A
Additional proxy soliciting materials
21 Dec 18
DEF 14A
Definitive proxy
10 Dec 18
DEF 14A
Definitive proxy
7 Dec 17
DEF 14A
Definitive proxy
12 Dec 16
DEF 14A
Definitive proxy
8 Dec 15
PRE 14A
Preliminary proxy
27 Nov 15
DEF 14A
Definitive proxy
16 Dec 14
DEF 14A
Definitive proxy
17 Dec 13
PRE 14A
Preliminary proxy
6 Dec 13
DEF 14A
Definitive proxy
18 Dec 12
Other
CT ORDER
Confidential treatment order
27 Feb 19
UPLOAD
Letter from SEC
26 Apr 17
CORRESP
Correspondence with SEC
29 Mar 17
UPLOAD
Letter from SEC
16 Mar 17
CORRESP
Correspondence with SEC
7 Mar 17
UPLOAD
Letter from SEC
23 Feb 17
UPLOAD
Letter from SEC
11 Mar 16
CORRESP
Correspondence with SEC
19 Feb 16
UPLOAD
Letter from SEC
9 Feb 16
CT ORDER
Confidential treatment order
11 Jan 16